Eli Lilly presented early clinical data for brenipatide, its once-weekly GIP/GLP-1 receptor agonist candidate designed to engage central nervous system and inflammatory pathways tied to reward and addiction biology. At Psych Congress 2026 in New Orleans, Lilly reported dose-selection support from a Phase I study (J2S-MC-GZMD; NCT06606106). In the poster, Lilly described brenipatide pharmacokinetics consistent with a durability of exposure that extends beyond weekly dosing—an attribute the company said it is testing in the neuroscience space. Reported mean half-life ranged from 9.08 to 12.5 days, with longer half-life in higher-dose cohorts. Lilly’s Phase III plans laid out in the presentation include evaluation of brenipatide in major depressive disorder (MDD) and alcohol use disorder (AUD), extending the company’s GLP-1–derived platform into psychiatric and substance-use targets. For the field, the program is notable because it reframes the obesity-and-diabetes franchise chemistry toward neuroinflammatory and reward-circuit hypotheses, setting up a head-to-head competitive challenge with other CNS-directed metabolic agents.